Olmstead County (Mayo) population study shows 47 lupus nephritis (LN) pts betw 1976-2018. Incidence doubled from 1980s (0.6 per 100K) to 2018 (1.2/100K); with women of childbearing age as the most affected group. #ACR20 Abstr#0274 https://t.co/uhAMd0EtJl

#ACR20 2F053. What is the future for GCA imaging? @RheumNow

Excellent session on large vessel vasculitis imaging with @petercgrayson @anisha_dua #ACR20 @RheumNow https://t.co/up5ZcGDnPt

Congrats to the #ACR20 Winning Image!! (click on exhibit and support tab and then on image competition to view all images) @rheumnow https://t.co/B3fcDSrfOf

Still more interesting lessons from GiACTA, this time re: nature of GCA flares on TCZ: - visual manifestation flares were rare - ESR or CRP raised in 3/4 of flares (so not raised in 1/4) Understanding these flares is crucial! Unizony et al @MGHMedicine #ACR20 ABST0516 @RheumNow https://t.co/WVIitov7Ut

Methotrexate and Nonalcoholic Fatty Liver Disease: Dr Eric Dein (@ejdein1) Dr. Eric Dein discusses the findings of abstract #0181 at the #ACR20 annual meeting. https://t.co/TzbRRbw1Kf https://t.co/vK6EahTyQ8

• https://bit.ly/32ktuj8

Diagnosis in GCA is changing. Some questions from these nice Olmsted County data: - why are dx in women declining? - in the past, without imaging, were we missing GCA diagnoses? It's easy to forget how far we've come in GCA! @MayoClinic @MdWarrington #ACR20 ABST0517 @RheumNow https://t.co/QsW8BSsf1a

@RheumNow #acr20 abs0063 in silico, in vitro &clinical study: Amitriptyline, naloxone& thalidomide prevent NOS2, IL6, IL1B, MMP9 release, inhibits NLRP3 inflammasome pathway> decreased colchicine consumption in gout pts using above meds for other indications #acrbest #different https://t.co/cz3htmtBU0

GCA phenotypic differences clearer again - Large vessel involvement (on USS) in GCA are a/w: - higher steroid burden - first relapses occur later - relapses harder to diagnose (symptoms less classical), but were a/w an IMT increase of about 25% (0.18mm) #ACR20 ABST0518 @RheumNow https://t.co/87zVjAm9eU

VA Population study shows that incident RA was less common in persons w/ HIV (PWH)(matched w/ uninfected). Only 21 RA pts in 56K PWH. PWH+/RA+ have lower autoantibodies and less likely to get DMARDs. #ACR20 Abstr#0195 https://t.co/rERJVQfq7a https://t.co/g5lATtxqOM

• https://meet.acrconvergence.org/meetings/virtual/DWuTqfxWNbdeSAimz

An emerging change in diagnostic (dx) modalities used in GCA? Although the leading dx modality remains a temporal a bx at 67% from 2010-2018, this is a decrease from 84% (1950-2009). Imaging is being used 19% of the time from 2010-2018 per data from Mayo Clinic. @RheumNow #ACR20 https://t.co/J97oVAGObj

• https://twitter.com/mdwarrington/status/1324827948633960453

ILD in SSc has grave consequences. Abstr#393 Claims database in Ontario shows relevant Scleroderma ILD occurred in 17% of >3000 pts with nearly double the mortality #ACR20 @RheumNow @CRASCRRheum #bestinclass https://t.co/K3UXvuxBcp

Shoutout to @SattuiSEMD and @NavarroMillanMD showing #dementia is lower in #RA pts on bDMARDs compared to csDMARDs using CMS data #ACR20 ABS#0488 @RADoctor @RheumNow https://t.co/1XOV2zqKko

Great talk by @rheumcat @rheum_covid on COVID-19 impact on rheumatology. Talk to pts re: what to do with rheum rx... they haven't read guidelines and may make their own changes! Prepare them for exposure/ifn! #ACR20 @Rheumnow 2F042 https://t.co/HkxbkYjEm3

@RheumNow #acr20 abs0405 RELIF ph3 rct: pts w/Behcets who achieve Full resolution of OUs w/Apremilast by wk6+ 6wks of sustained response also report better improvement in BSAS, OU pain, overall Dis activity& QoL. Only 29.8% were able to achieve 6+6 though, while 70.2% did not https://t.co/8roaO5YPM6